# Pulmonx Corp: financial statements, quarterly

LUNG · Nasdaq · CIK 1127537 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lung.md) · [Financials](/companies/lung/financials.md) · [Filings](/companies/lung/filings.md) · [Insiders](/companies/lung/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lung/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [17.7](/filings/0001127537-24-000087.md) | [19.3 d](/filings/0001127537-25-000012.md) | [18.9](/filings/0001127537-25-000026.md) | [20.8](/filings/0001127537-25-000045.md) | [20.4](/filings/0001127537-25-000059.md) | [23.8 d](/filings/0001127537-26-000015.md) | [22.5](/filings/0001127537-26-000025.md) | [23.9](/filings/0001127537-26-000039.md) | [21.5](/filings/0001127537-25-000059.md) | [22.6 d](/filings/0001127537-26-000015.md) | [20.6](/filings/0001127537-26-000025.md) | [22.8](/filings/0001127537-26-000039.md) |
| Cost of revenue | $m | [4.6](/filings/0001127537-24-000087.md) | [4.9 d](/filings/0001127537-25-000012.md) | [4.8](/filings/0001127537-25-000026.md) | [5.5](/filings/0001127537-25-000045.md) | [5.4](/filings/0001127537-25-000059.md) | [6.2 d](/filings/0001127537-26-000015.md) | [6.2](/filings/0001127537-26-000025.md) | [6.7](/filings/0001127537-26-000039.md) | [5.5](/filings/0001127537-25-000059.md) | [5.1 d](/filings/0001127537-26-000015.md) | [4.5](/filings/0001127537-26-000025.md) | [5.0](/filings/0001127537-26-000039.md) |
| Gross profit | $m | [13.0](/filings/0001127537-24-000087.md) | [14.4 d](/filings/0001127537-25-000012.md) | [14.1](/filings/0001127537-25-000026.md) | [15.3](/filings/0001127537-25-000045.md) | [15.0](/filings/0001127537-25-000059.md) | [17.6 d](/filings/0001127537-26-000015.md) | [16.3](/filings/0001127537-26-000025.md) | [17.2](/filings/0001127537-26-000039.md) | [16.1](/filings/0001127537-25-000059.md) | [17.5 d](/filings/0001127537-26-000015.md) | [16.0](/filings/0001127537-26-000025.md) | [17.7](/filings/0001127537-26-000039.md) |
| Research and development | $m | [4.2](/filings/0001127537-24-000087.md) | [3.9 d](/filings/0001127537-25-000012.md) | [4.2](/filings/0001127537-25-000026.md) | [5.6](/filings/0001127537-25-000045.md) | [3.7](/filings/0001127537-25-000059.md) | [4.0 d](/filings/0001127537-26-000015.md) | [4.8](/filings/0001127537-26-000025.md) | [5.3](/filings/0001127537-26-000039.md) | [4.8](/filings/0001127537-25-000059.md) | [4.6 d](/filings/0001127537-26-000015.md) | [4.9](/filings/0001127537-26-000025.md) | [5.0](/filings/0001127537-26-000039.md) |
| Selling, general and administrative | $m | [24.0](/filings/0001127537-24-000087.md) | [24.4 d](/filings/0001127537-25-000012.md) | [24.4](/filings/0001127537-25-000026.md) | [25.3](/filings/0001127537-25-000045.md) | [25.4](/filings/0001127537-25-000059.md) | [27.0 d](/filings/0001127537-26-000015.md) | [26.1](/filings/0001127537-26-000025.md) | [26.7](/filings/0001127537-26-000039.md) | [25.6](/filings/0001127537-25-000059.md) | [22.9 d](/filings/0001127537-26-000015.md) | [24.1](/filings/0001127537-26-000025.md) | [21.8](/filings/0001127537-26-000039.md) |
| Operating income | $m | [(15.2)](/filings/0001127537-24-000087.md) | [(13.9) d](/filings/0001127537-25-000012.md) | [(14.5)](/filings/0001127537-25-000026.md) | [(15.6)](/filings/0001127537-25-000045.md) | [(14.1)](/filings/0001127537-25-000059.md) | [(13.4) d](/filings/0001127537-26-000015.md) | [(14.6)](/filings/0001127537-26-000025.md) | [(14.8)](/filings/0001127537-26-000039.md) | [(14.4)](/filings/0001127537-25-000059.md) | [(9.9) d](/filings/0001127537-26-000015.md) | [(13.0)](/filings/0001127537-26-000025.md) | [(9.1)](/filings/0001127537-26-000039.md) |
| Interest expense | $m | [0.9](/filings/0001127537-23-000048.md) | [0.9 d](/filings/0001127537-24-000024.md) | [0.9](/filings/0001127537-24-000052.md) | [0.9](/filings/0001127537-25-000045.md) | [0.9](/filings/0001127537-25-000059.md) | [0.8 d](/filings/0001127537-26-000015.md) | [0.8](/filings/0001127537-26-000025.md) | [0.8](/filings/0001127537-26-000039.md) | [0.8](/filings/0001127537-25-000059.md) | [0.8 d](/filings/0001127537-26-000015.md) | [1.0](/filings/0001127537-26-000025.md) | [1.2](/filings/0001127537-26-000039.md) |
| Income tax | $m | [0.1](/filings/0001127537-24-000087.md) | [0.2 d](/filings/0001127537-25-000012.md) | [0.2](/filings/0001127537-25-000026.md) | [0.1](/filings/0001127537-25-000045.md) | [0.2](/filings/0001127537-25-000059.md) | [0.0 d](/filings/0001127537-26-000015.md) | [0.1](/filings/0001127537-26-000025.md) | [0.2](/filings/0001127537-26-000039.md) | [0.1](/filings/0001127537-25-000059.md) | [0.2 d](/filings/0001127537-26-000015.md) | [0.1](/filings/0001127537-26-000025.md) | [0.1](/filings/0001127537-26-000039.md) |
| Net income | $m | [(14.9)](/filings/0001127537-24-000087.md) | [(13.9) d](/filings/0001127537-25-000012.md) | [(13.7)](/filings/0001127537-25-000059.md) | [(15.3)](/filings/0001127537-25-000059.md) | [(14.1)](/filings/0001127537-25-000059.md) | [(13.2) d](/filings/0001127537-26-000015.md) | [(14.4)](/filings/0001127537-26-000039.md) | [(15.2)](/filings/0001127537-26-000039.md) | [(14.0)](/filings/0001127537-25-000059.md) | [(10.4) d](/filings/0001127537-26-000015.md) | [(13.7)](/filings/0001127537-26-000039.md) | [(10.1)](/filings/0001127537-26-000039.md) |
| Diluted EPS | $ per share | [(0.39)](/filings/0001127537-24-000087.md) | not reported | [(0.36)](/filings/0001127537-25-000026.md) | [(0.39)](/filings/0001127537-25-000045.md) | [(0.36)](/filings/0001127537-25-000059.md) | not reported | [(0.36)](/filings/0001127537-26-000025.md) | [(0.38)](/filings/0001127537-26-000039.md) | [(0.34)](/filings/0001127537-25-000059.md) | not reported | [(0.33)](/filings/0001127537-26-000025.md) | [(0.24)](/filings/0001127537-26-000039.md) |
| Basic EPS | $ per share | [(0.39)](/filings/0001127537-24-000087.md) | not reported | [(0.36)](/filings/0001127537-25-000026.md) | [(0.39)](/filings/0001127537-25-000045.md) | [(0.36)](/filings/0001127537-25-000059.md) | not reported | [(0.36)](/filings/0001127537-26-000025.md) | [(0.38)](/filings/0001127537-26-000039.md) | [(0.34)](/filings/0001127537-25-000059.md) | not reported | [(0.33)](/filings/0001127537-26-000025.md) | [(0.24)](/filings/0001127537-26-000039.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [94.9](/filings/0001127537-24-000087.md) | [83.5](/filings/0001127537-25-000012.md) | [70.2](/filings/0001127537-25-000026.md) | [63.5](/filings/0001127537-25-000045.md) | [63.3](/filings/0001127537-25-000059.md) | [70.9](/filings/0001127537-26-000015.md) | [74.6](/filings/0001127537-26-000025.md) | [75.5](/filings/0001127537-26-000039.md) | [76.5](/filings/0001127537-25-000059.md) | [69.8](/filings/0001127537-26-000039.md) | [61.6](/filings/0001127537-26-000025.md) | [55.8](/filings/0001127537-26-000039.md) |
| Current assets | $m | [147](/filings/0001127537-23-000048.md) | [150](/filings/0001127537-25-000012.md) | [148](/filings/0001127537-24-000052.md) | [146](/filings/0001127537-24-000077.md) | [141](/filings/0001127537-24-000087.md) | [136](/filings/0001127537-26-000015.md) | [124](/filings/0001127537-25-000026.md) | [120](/filings/0001127537-25-000045.md) | [111](/filings/0001127537-25-000059.md) | [102](/filings/0001127537-26-000039.md) | [92.7](/filings/0001127537-26-000025.md) | [88.1](/filings/0001127537-26-000039.md) |
| Total assets | $m | [185](/filings/0001127537-23-000048.md) | [178](/filings/0001127537-25-000012.md) | [165](/filings/0001127537-24-000052.md) | [173](/filings/0001127537-24-000077.md) | [167](/filings/0001127537-24-000087.md) | [163](/filings/0001127537-26-000015.md) | [151](/filings/0001127537-25-000026.md) | [147](/filings/0001127537-25-000045.md) | [138](/filings/0001127537-25-000059.md) | [129](/filings/0001127537-26-000039.md) | [120](/filings/0001127537-26-000025.md) | [115](/filings/0001127537-26-000039.md) |
| Current liabilities | $m | [20.5](/filings/0001127537-23-000048.md) | [23.2](/filings/0001127537-25-000012.md) | [21.3](/filings/0001127537-24-000052.md) | [16.3](/filings/0001127537-24-000077.md) | [18.3](/filings/0001127537-24-000087.md) | [24.4](/filings/0001127537-26-000015.md) | [24.9](/filings/0001127537-25-000026.md) | [22.4](/filings/0001127537-25-000045.md) | [22.9](/filings/0001127537-25-000059.md) | [20.1](/filings/0001127537-26-000039.md) | [18.9](/filings/0001127537-26-000025.md) | [20.4](/filings/0001127537-26-000039.md) |
| Total liabilities | $m | [59.3](/filings/0001127537-23-000048.md) | [59.5](/filings/0001127537-25-000012.md) | [54.1](/filings/0001127537-24-000052.md) | [71.4](/filings/0001127537-24-000077.md) | [73.5](/filings/0001127537-24-000087.md) | [77.0](/filings/0001127537-26-000015.md) | [73.1](/filings/0001127537-25-000026.md) | [78.1](/filings/0001127537-25-000045.md) | [78.2](/filings/0001127537-25-000059.md) | [75.2](/filings/0001127537-26-000039.md) | [74.2](/filings/0001127537-26-000025.md) | [75.5](/filings/0001127537-26-000039.md) |
| Long-term debt | $m | [37.2](/filings/0001127537-23-000048.md) | [35.1](/filings/0001127537-25-000012.md) | [32.0](/filings/0001127537-24-000052.md) | [37.1](/filings/0001127537-24-000077.md) | [37.1](/filings/0001127537-24-000087.md) | [34.0](/filings/0001127537-26-000015.md) | [29.4](/filings/0001127537-25-000026.md) | [37.0](/filings/0001127537-25-000045.md) | [37.0](/filings/0001127537-25-000059.md) | [37.0](/filings/0001127537-26-000039.md) | [37.2](/filings/0001127537-26-000025.md) | [37.4](/filings/0001127537-26-000039.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [0.1](/filings/0001127537-23-000048.md) | [2.2](/filings/0001127537-25-000012.md) | [5.2](/filings/0001127537-24-000052.md) | [0.1](/filings/0001127537-24-000077.md) | [0.1](/filings/0001127537-24-000087.md) | [3.2](/filings/0001127537-26-000015.md) | [7.8](/filings/0001127537-25-000026.md) | [0.1](/filings/0001127537-25-000045.md) | [0.1](/filings/0001127537-25-000059.md) | [0.1](/filings/0001127537-26-000039.md) | [0.1](/filings/0001127537-26-000025.md) | [0.1](/filings/0001127537-26-000039.md) |
| Shareholders' equity | $m | [126](/filings/0001127537-24-000087.md) | [118](/filings/0001127537-26-000015.md) | [110](/filings/0001127537-25-000059.md) | [101](/filings/0001127537-25-000059.md) | [93.9](/filings/0001127537-25-000059.md) | [85.8](/filings/0001127537-26-000039.md) | [77.7](/filings/0001127537-26-000039.md) | [69.1](/filings/0001127537-26-000039.md) | [60.0](/filings/0001127537-25-000059.md) | [54.1](/filings/0001127537-26-000039.md) | [45.8](/filings/0001127537-26-000039.md) | [39.2](/filings/0001127537-26-000039.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.6) d](/filings/0001127537-24-000087.md) | [(8.4) d](/filings/0001127537-25-000012.md) | [(11.8)](/filings/0001127537-25-000026.md) | [(5.8) d](/filings/0001127537-25-000045.md) | [(7.2) d](/filings/0001127537-25-000059.md) | [(6.7) d](/filings/0001127537-26-000015.md) | [(13.2)](/filings/0001127537-26-000025.md) | [(3.9) d](/filings/0001127537-26-000039.md) | [(8.2) d](/filings/0001127537-25-000059.md) | [(7.1) d](/filings/0001127537-26-000015.md) | [(10.1)](/filings/0001127537-26-000025.md) | [(5.2) d](/filings/0001127537-26-000039.md) |
| Capital expenditure | $m | [0.5 d](/filings/0001127537-24-000087.md) | [0.2 d](/filings/0001127537-25-000012.md) | [0.5](/filings/0001127537-25-000026.md) | [0.5 d](/filings/0001127537-25-000045.md) | [0.4 d](/filings/0001127537-25-000059.md) | [0.1 d](/filings/0001127537-26-000015.md) | [0.3](/filings/0001127537-26-000025.md) | [0.0 d](/filings/0001127537-26-000039.md) | [0.1 d](/filings/0001127537-25-000059.md) | [0.0 d](/filings/0001127537-26-000015.md) | [0.0](/filings/0001127537-26-000025.md) | [0.0 d](/filings/0001127537-26-000039.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [37.2](/filings/0001127537-23-000048.md) | [37.6](/filings/0001127537-24-000052.md) | [37.8](/filings/0001127537-24-000077.md) | [38.1](/filings/0001127537-24-000087.md) | [38.6](/filings/0001127537-25-000026.md) | [38.9](/filings/0001127537-25-000045.md) | [39.3](/filings/0001127537-25-000059.md) | [40.0](/filings/0001127537-26-000025.md) | [40.4](/filings/0001127537-26-000039.md) | [40.9](/filings/0001127537-25-000059.md) | [41.9](/filings/0001127537-26-000025.md) | [42.5](/filings/0001127537-26-000039.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 42,948,269 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001127537-26-000039.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.